In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.
作者信息
Tsume Yasuhiro, Patel Sanjaykumar, Fotaki Nikoletta, Bergstrӧm Christel, Amidon Gordon L, Brasseur James G, Mudie Deanna M, Sun Duxin, Bermejo Marival, Gao Ping, Zhu Wei, Sperry David C, Vertzoni Maria, Parrott Neil, Lionberger Robert, Kambayashi Atsushi, Hermans Andre, Lu Xujin, Amidon Gregory E
机构信息
College of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109, USA.
Merck & Co., Inc., 126 E Lincoln Ave, Rahway, New Jersey, 07065, USA.
出版信息
AAPS J. 2018 Sep 6;20(6):100. doi: 10.1208/s12248-018-0260-3.
Abstract
摘要
相似文献
1
In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.
AAPS J. 2018 Sep 6;20(6):100. doi: 10.1208/s12248-018-0260-3.
2
Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
Eur J Pharm Biopharm. 2018 Aug;129:222-246. doi: 10.1016/j.ejpb.2018.05.024. Epub 2018 Jun 4.
3
Dissolution profiles of BCS class II drugs generated by the gastrointestinal simulator alpha has an edge over the compendial USP II method.
Eur J Pharm Biopharm. 2024 Oct;203:114436. doi: 10.1016/j.ejpb.2024.114436. Epub 2024 Aug 5.
4
Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Mol Pharm. 2021 Sep 6;18(9):3326-3341. doi: 10.1021/acs.molpharmaceut.1c00262. Epub 2021 Aug 24.
5
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Eur J Pharm Biopharm. 2020 Oct;155:55-68. doi: 10.1016/j.ejpb.2020.08.005. Epub 2020 Aug 8.
6
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Eur J Pharm Sci. 2014 Jun 16;57:152-63. doi: 10.1016/j.ejps.2014.01.009. Epub 2014 Jan 28.
7
Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Eur J Pharm Sci. 2014 Jun 16;57:173-99. doi: 10.1016/j.ejps.2013.10.015. Epub 2013 Nov 9.
8
Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.
CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):492-495. doi: 10.1002/psp4.12204. Epub 2017 Jul 11.
9
Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs.
Int J Pharm. 2019 Feb 10;556:45-56. doi: 10.1016/j.ijpharm.2018.11.072. Epub 2018 Dec 7.
10
Drug dissolution: significance of physicochemical properties and physiological conditions.
Drug Discov Today. 2013 Dec;18(23-24):1173-84. doi: 10.1016/j.drudis.2013.08.013. Epub 2013 Sep 13.
引用本文的文献
1
Focusing on First Cycle Approval in ANDA Submission: Understanding Common Deficiencies & Case Study Insights.
Ther Innov Regul Sci. 2025 May;59(3):426-437. doi: 10.1007/s43441-025-00755-5. Epub 2025 Feb 8.
2
Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging.
Pharmaceutics. 2021 Oct 19;13(10):1729. doi: 10.3390/pharmaceutics13101729.
3
Current trends in drug metabolism and pharmacokinetics.
Acta Pharm Sin B. 2019 Nov;9(6):1113-1144. doi: 10.1016/j.apsb.2019.10.001. Epub 2019 Oct 18.
本文引用的文献
1
In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
Mol Pharm. 2017 Dec 4;14(12):4295-4304. doi: 10.1021/acs.molpharmaceut.7b00425. Epub 2017 Oct 5.
2
The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
J Pharm Sci. 2018 Jan;107(1):307-316. doi: 10.1016/j.xphs.2017.09.002. Epub 2017 Sep 15.
3
In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance.
Mol Pharm. 2017 Nov 6;14(11):3801-3814. doi: 10.1021/acs.molpharmaceut.7b00552. Epub 2017 Sep 27.
4
Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
Mol Pharm. 2017 Dec 4;14(12):4281-4294. doi: 10.1021/acs.molpharmaceut.7b00426. Epub 2017 Aug 4.
5
Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method.
J Pharm Sci. 2018 Jan;107(1):476-487. doi: 10.1016/j.xphs.2017.06.018. Epub 2017 Jun 27.
6
Impact of Drug-Rich Colloids of Itraconazole and HPMCAS on Membrane Flux in Vitro and Oral Bioavailability in Rats.
Mol Pharm. 2017 Jul 3;14(7):2437-2449. doi: 10.1021/acs.molpharmaceut.7b00338. Epub 2017 Jun 22.
7
Development of a Biorelevant, Material-Sparing Membrane Flux Test for Rapid Screening of Bioavailability-Enhancing Drug Product Formulations.
Mol Pharm. 2017 Jun 5;14(6):2032-2046. doi: 10.1021/acs.molpharmaceut.7b00121. Epub 2017 May 10.
8
Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
Mol Pharm. 2017 Dec 4;14(12):4181-4191. doi: 10.1021/acs.molpharmaceut.6b01129. Epub 2017 Apr 13.
9
The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Eur J Pharm Sci. 2017 May 1;102:126-139. doi: 10.1016/j.ejps.2017.02.042. Epub 2017 Mar 3.
10
Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
AAPS J. 2017 May;19(3):827-836. doi: 10.1208/s12248-017-0060-1. Epub 2017 Feb 24.
Zotero 插件